Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.08USD
7 Aug 2020
Change (% chg)

$-0.03 (-2.70%)
Prev Close
$1.11
Open
$1.08
Day's High
$1.09
Day's Low
$1.08
Volume
108,559
Avg. Vol
934,437
52-wk High
$1.97
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Moleculin Announces Agreement To Produce WP1122 For Expanded Development Of Potential Covid-19 And Oncology Drug Candidate
Wednesday, 15 Jul 2020 

July 15 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES AGREEMENT TO PRODUCE WP1122 FOR EXPANDED DEVELOPMENT OF POTENTIAL COVID-19 AND ONCOLOGY DRUG CANDIDATE.MOLECULIN BIOTECH INC - ENTERED INTO AN AGREEMENT WITH STERLING PHARMA USA LLC.MOLECULIN BIOTECH - EXPANDING PLANNED PRECLINICAL STUDIES FOR IND, INCLUDING TESTING MULTIPLE ANALOGS OF WP1122 AGAINST VARIOUS VIRUSES IN VITRO.MOLECULIN BIOTECH INC - PLANNED TESTS ARE INTENDED TO PROVIDE ADDITIONAL COMPARATIVE DATA OF WP1122 AND ITS CLOSE ANALOGS.MOLECULIN BIOTECH INC - BELIEVES MECHANISM OF ACTION OF 2-DG AND WP1122 IS VERY DIFFERENT FROM OTHER DRUGS BEING DEVELOPED FOR COVID-19.MOLECULIN BIOTECH INC - COMPANY WILL SEEK TO EVALUATE WP1122 IN AN ANIMAL MODEL FOR COVID-19 AS A PART OF ITS IND PREPARATION.MOLECULIN BIOTECH -BELIEVE CONVENTIONAL METHODS OF ANTIVIRAL TESTING MAY NOT BE IDEALLY SUITED TO TEST CLASS OF AGENTS REPRESENTED BY 2-DG & WP1122.  Full Article

Moleculin Provides Update On Annamycin Clinical Development
Thursday, 2 Jul 2020 

July 2 (Reuters) - Moleculin Biotech Inc ::MOLECULIN PROVIDES UPDATE ON ANNAMYCIN CLINICAL DEVELOPMENT.MOLECULIN BIOTECH INC - AGREED TO EXPAND ITS PROTOCOL-MANDATED TESTING FOR CARDIOTOXICITY THROUGHOUT REMAINDER OF ITS EUROPEAN PHASE 1 TRIAL.MOLECULIN BIOTECH - BELIEVES THAT EUROPEAN DOSING WILL INCREASE IN 2020, ALLOWING A RECOMMENDED PHASE 2 DOSE TO BE ESTABLISHED IN 2021.MOLECULIN BIOTECH - HOPES TO FILE AN IND APPLICATION OR ITS EUROPEAN EQUIVALENT OF ANNAMYCIN FOR TREATMENT OF LUNG METASTASES BY END OF THIS YEAR.  Full Article

Moleculin Announces Confirmatory In Vitro Analysis Of WP1122
Tuesday, 16 Jun 2020 

June 16 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES CONFIRMATORY IN VITRO ANALYSIS OF WP1122.MOLECULIN BIOTECH INC - ANNOUNCED THAT A REPEAT OF PREVIOUS IN VITRO TESTING HAS CORROBORATED ANTIVIRAL POTENTIAL OF WP1122.MOLECULIN BIOTECH - RESULTS OF REPEATED ROUND OF IN VITRO TESTING RECEIVED, CONFIRM WP1122 HAS AN ANTIVIRAL EFFECT ON HUMAN CORONAVIRUS 229E.MOLECULIN BIOTECH - EXPECTS TO FILE REQUEST FOR IND STATUS TO TEST WP1122 FOR TREATMENT OF COVID-19 PATIENTS DURING H2 2020.  Full Article

Moleculin Reports Submission To Expand Clinical Sites In European AML Trial
Thursday, 4 Jun 2020 

June 4 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES SUBMISSION TO EXPAND CLINICAL SITES IN EUROPEAN AML TRIAL.MOLECULIN BIOTECH - SUBMITS REGULATORY REQUESTS TO OPEN TWO ADDITIONAL CLINICAL SITES IN POLAND.MOLECULIN BIOTECH - ASSUMING REQUESTS ARE GRANTED, EXPECT ADDITIONAL SITES TO BEGIN RECRUITING IN Q3.  Full Article

Moleculin Provides Update On Coronavirus Drug Development
Thursday, 28 May 2020 

May 27 (Reuters) - Moleculin Biotech Inc ::MOLECULIN PROVIDES UPDATE ON CORONAVIRUS DRUG DEVELOPMENT.MOLECULIN BIOTECH - FDA HAS GRANTED CO'S REQUEST FOR A PRE-IND MEETING TO PROVIDE GUIDANCE REGARDING PLAN TO STUDY ITS DRUG CANDIDATE, WP1122.MOLECULIN BIOTECH INC - ESTIMATE THAT CO SHOULD BE ABLE TO SUBMIT IND APPLICATION IN SECOND HALF OF THIS YEAR.MOLECULIN BIOTECH INC - INITIAL RESULTS RECEIVED ON MAY 4, 2020 SHOW THAT BOTH 2-DG AND WP1122 HAVE AN ANTIVIRAL EFFECT ON HCOV-229E.  Full Article

Moleculin Provides Additional Comments Regarding Trading Halt
Monday, 11 May 2020 

Moleculin Biotech Inc ::MOLECULIN PROVIDES ADDITIONAL COMMENTS REGARDING TRADING HALT.MOLECULIN BIOTECH - SINCE TEMPORARY SUSPENSION BY SEC, ADDITIONAL DATA HAS COME TO CO'S ATTENTION REGARDING CLAIMS DISSEMINATED BY THIRD PARTIES.MOLECULIN BIOTECH - LEARNED THAT SOME THIRD PARTIES MADE CLAIMS & DISTRIBUTED INFORMATION DURING PERIOD BETWEEN MARCH 20 TO MAY 5.MOLECULIN BIOTECH - LEARNED THAT THIRD PARTIES MADE CLAIMS ABOUT POTENTIAL EFFICACY & CLINICAL DEVELOPMENT OF WP1122 WITH RESPECT TO CORONAVIRUS.MOLECULIN BIOTECH - SEC'S SUSPENSION OF TRADING MOLECULIN STOCK IS SCHEDULED TO TERMINATE AT 11:59 P.M. ET ON MAY 15.  Full Article

Moleculin Announces Agreement With Imquest Biosciences To Expand Coronavirus Testing
Monday, 20 Apr 2020 

April 20 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES AGREEMENT WITH IMQUEST BIOSCIENCES TO EXPAND CORONAVIRUS TESTING.MOLECULIN BIOTECH INC - ENTERED INTO AN AGREEMENT WITH IMQUEST BIOSCIENCES TO EXPAND IN VITRO AND IN VIVO TESTING OF WP1122.MOLECULIN BIOTECH - TO GENERATE CRITICAL DATA OVER NEXT 4 TO 8 WEEKS THAT CO HOPE WILL SUPPORT AN IND SUBMISSION IN U.S. AND A CTA REQUEST IN EUROPE.  Full Article

Moleculin Biotech - Received A Deficiency Letter From Listing Qualifications Department Of Nasdaq
Friday, 27 Mar 2020 

March 26 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC - RECEIVED A DEFICIENCY LETTER FROM LISTING QUALIFICATIONS DEPARTMENT OF NASDAQ.  Full Article

Moleculin Biotech Reports Financial Results For The Year Ended December 31, 2019
Friday, 20 Mar 2020 

March 19 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2019.MOLECULIN BIOTECH - BELIEVE THAT CASH RESOURCES AS OF DEC 31, 2019, ADDITIONAL FUNDING RECEIVED, SUFFICIENT TO MEET PROJECTED OPERATING REQUIREMENTS TOWWARDS END OF Q3 2020.  Full Article

Moleculin To Seek Accelerated FDA Approval And Plans For Pivotal Phase 2 Aml Trial
Wednesday, 5 Feb 2020 

Moleculin Biotech Inc ::MOLECULIN TO SEEK ACCELERATED FDA APPROVAL AND PLANS FOR PIVOTAL PHASE 2 AML TRIAL.MOLECULIN BIOTECH INC - MOLECULIN WILL CONTINUE TO FOCUS COMPANY'S EFFORTS ON EUROPEAN TRIAL TO ESTABLISH AN RP2D.MOLECULIN BIOTECH INC - INTENDS TO ENTER DISCUSSIONS WITH FDA AND EMA ABOUT CONDUCTING A SINGLE ARM PHASE 2 STUDY.MOLECULIN BIOTECH INC - U.S. PHASE 1 TRIAL MET ITS PRIMARY ENDPOINT, DEMONSTRATING SAFETY OF ANNAMYCIN IN AML PATIENTS.  Full Article